 To study the plasma pharmacokinetics of posaconazole in patients with newly diagnosed acute myelogenous leukemia AML or high-risk myelodysplastic syndrome HR-MDS undergoing induction chemotherapy or relapsed or refractory patients who will receive salvage chemotherapy. 